ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta ...

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...

XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...

Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...

"Imugene announces Phase Ib azer-cel efficacy data" was originally created and published by Clinical Trials Arena, a ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T. Efficacy outcomes in complete responders with LBCL (n=65). Data cutoff: October 16, ...